NeuroDerm Ltd. NDRM
No live quote for NDRM yet.
Analyst view
Consensus: buy
Buy
Price target (mean) 47.50
- Target (low)
- 39.00
- Target (mean)
- 47.50
- Target (high)
- 70.00
Ratings (-2m) 4 2 buy · 2 hold · 0 sell
- Strong buy1
- Buy1
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- 2 months ago 4
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56 | -0.56 – -0.56 | -0.42 | -33.3% | 0 | 0.0% | 1 |
| Next quarter | -0.58 | -0.58 – -0.58 | -0.49 | -18.4% | 0 | 0.0% | 1 |
| Current year | -2.20 | -2.20 – -2.20 | -1.48 | -48.6% | 0 | 0.0% | 1 |
| Next year | -1.95 | -1.95 – -1.95 | -2.20 | +11.4% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 1, 2017 | Roth Capital | Downgrade | Buy | Neutral |
| Jul 20, 2017 | Deutsche Bank | Initiated | — | Buy |
| Jun 13, 2017 | Oppenheimer | Upgrade | — | Outperform |
| Mar 6, 2017 | Oppenheimer | Downgrade | — | Perform |
| Nov 9, 2015 | Raymond James | Initiated | — | Outperform |
| Apr 22, 2015 | Jefferies | Initiated | — | Buy |
| Dec 8, 2014 | Roth Capital | Initiated | — | Buy |